LiquidGx_tm LiquidGx
A non-invasive cancer test that can easily become part of your workflow
LiquidGX_iocn1 LiquidGx
Established guidelines
recommend liquid biopsy
when tissue biopsy is not
LiquidGX_iocn2 LiquidGx
Utilizes proprietary
technology to analyze
ctDNA/RNA to accurately
detect cancer-driving
LiquidGX_iocn3 LiquidGx
Measures actionable
mutations from blood for
the selection of solid tumor
targeted treatment
LiquidGX_iocn4 LiquidGx
Testing at multiple time
points allows
quantitative monitoring
for drug resistance
Clear, Color-Coded Results

Same_Tumor_Type_icon_green LiquidGx

Therapies with Potential Clinical Benefit

Recommends FDA-approved drugs for
that indication

Different_Tumor_Type_icon_blue LiquidGx

Therapies with Potential Clinical Benefit

FDA-approved drugs for other indications
that may be beneficial

Lack_of_clinical_benefit_icon LiquidGx

Lack of Clinical Benefit

Drugs that will likely not show any benefit
due to the presence of resistant markers

clinical_trials_icon_purple LiquidGx

Clinical Trials
to Consider

For each variant found, will provide up to 5
relevant clinical trials with geographic

Download_Sample_Report_Maroon_small LiquidGx
qPCR_Gene_Table LiquidGx
  • Single gene analytes via qPCR that can be
    run individually or multiplexed
  • Offers accurate results within 3-5 business
    days so results can be in-hand before a
    patient’s first oncology consultation
  • Limit-of-detection 0.01%, the equivalent of
    finding one DNA fragment in 10,000
  • EGFR T790M and EGFR C797S variant detection
    for drug resistance monitoring included
NGS_Gene_Table LiquidGx
  • Next Generation Sequencing test, coverage of >110
    variants in 10 genes frequently mutated in lung cancer
  • Turnaround time of 3-5 business days, which is
    faster than standard protocols including reflexive
    FISH and immunohistochemistry testing
  • Limit-of-detection 0.1%
  • Input includes both ctDNA and ctRNA allowing
    for optimal fusion detection including, novel fusions

LiquidGx™ NGS quantifiable detects variants – producing actionable results

         Also detectable by qPCR       

Genes Variants Potential Treatment Implications
AKT1 E17K May result in clinical trial recommendations
ALK  Fusions: EML4, KIF5B, TFG, STRN May benefit from treatment with crizotinib, ceritinib, or alectinib
L1196M, G1202R, I1171T/N/S, F1174L/S, E1210K, 1151Tins, C1156Y,L1198F,V1190L, D1203N, S1206Y/C, G1269A Predictive of crizotinib resistance. May demonstrate benefit with ceritinib, alectinib, and brigatinib
BRAF  V600E, V600K, V600D, V600G, V600M, V600R May benefit from treatment with
vemurafenib, dabrafenib,
vemurafenib + cibimetinib, or
dabrafenib + trametinib
L597R, L597Q,L597S, L597V, D594G, D594V May result in clinical trial recommendations
EGFR  L858R, E746_A750del, E746_A750delELREA, G719A, G719C, G719S, E746_S752delinsA, A763_Y7g4insFQEA, K745_A750del, L747_S752del, additional Exon19_del May benefit from treatment with gefitinib, erlotinib, or afatinib
Exon20_ins May demonstrate lack of clinical benefit to gefitinib and erlotinib
 T790M May benefit from treatment with osimertinib if previously treated with 1st or 2nd generation EGFR-TKIs
 C797S May demonstrate acquired resistance to osimertinib
ERBB2 Exon20_ins, G776L, G776_777insVC May benefit from treatment with trastuzumab and afatinib
KRAS  G12C, G12V, G12D, G12A, G12R, G12S,
G13D, G13D,
G13A, G13R, G13S, G13V,
Q61H, Q61K, Q61L, Q61P, Q61R
Often associated with poor prognosis including resistance to gefitinib, erlotinib, cetuximab, panitumumab
MET Exon14_skipping May benefit from treatment with crizotinib
PIK3CA E542K, E545K, H1047R May benefit from treatment with temsirolimus and everolimus
RET Fusions: CCDC6, NCOA4, KIF5B May benefit from treatment with vandetanib and cabozantinib
ROS1 Fusions: LRIG3, TPM3, EZR, SDC4, GOPC, SLC34A2, CD74 May benefit from treatment with crizotinib

LiquidGx™ complements Admera Health’s suite of molecular diagnostics:

OncoGxSelect_box LiquidGx
OncoGxOne_box LiquidGx
CardioGx_box-1 LiquidGx